Eli Lilly reported a 48% revenue increase to $23 billion in Q2 2026, driven mainly by strong sales of Mounjaro and Zepbound. Earnings per share rose 26% to $7.94 on a reported basis, with non-GAAP EPS up 33% to $8.38. The company raised its full-year 2026 revenue guidance to $85-$87 billion and updated EPS guidance to $35.50-$36.50, despite higher acquired IPR&D charges. Regulatory approvals and positive clinical trial results, especially for obesity drug retatrutide, support future growth prospects.
Since Medicare began covering obesity drugs in July, 700,000 new seniors have started GLP-1 treatments, with 70% using Eli Lilly's medicines. The coverage, part of a temporary "Bridge" program, allows eligible seniors to access weight loss drugs for ...
Eli Lilly reported a remarkable 48% revenue growth driven by strong sales of Mounjaro and Zepbound, yet its stock price remains nearly flat this year. Despite recent stock volatility due to price cuts, acquisition charges, and competition concerns, a...
Novo Nordisk's shares fell over 7% after the company announced long-term targets that failed to reassure investors about competition in the weight-loss drug market. The Danish drugmaker plans to launch multiple blockbuster drugs by 2030 and aims for ...
Nvidia and Eli Lilly both exceeded earnings expectations, but Nvidia's AI-driven data center growth offers a stronger long-term investment opportunity. Nvidia posted $96.22 billion in revenue, driven by AI infrastructure demand and supply constraints...
Novo Nordisk's stock fell 7% following its capital markets day where it outlined a growth plan that aligns with industry peers rather than exceeding them, signaling slower future growth. The company highlighted the upcoming loss of U.S. patent exclus...
